Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dupilumab in Chinese adults with chronic rhinosinusitis with nasal polyposis
NCT05878093Phase 3Completed
- Sponsor
- Sanofi
- Start
- May 2023
- Primary completion
- Sep 2024
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of dupilumab in chronic rhinosinusitis with nasal polyposis (CRSwNP), sponsored by Sanofi. Started May 2023; status: completed.
02
Drugs
03
Conditions
chronic rhinosinusitis with nasal polyposis (CRSwNP)
Beyond the preview
Go deeper on NCT05878093.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05878093.